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Obesity is a growing health problem worldwide. It is associated with an increased cardiovascular risk on the one hand of obesity itself
and on the other hand of associated medical conditions (hypertension, diabetes, insulin resistance, and sleep apnoea syndrome).
Obesity has an important role in atherosclerosis and coronary artery disease. Obesity leads to structural and functional changes of
the heart, which causes heart failure. The altered myocardial structure increases the risk of atrial ﬁbrillation and sudden cardiac
death. However, obesity also has a protective eﬀect on the clinical outcome of underlying cardiovascular disease, the phenomenon
called obesity paradox. The improved cardiac imaging techniques allow the early detection of altered structure and function of the
heart in obese patients. In this review, we attempt to summarize the relationship between obesity and cardiovascular diseases and
outline the underlying mechanisms. The demonstrated new techniques of cardiac diagnostic procedures allow for the early
detection and treatment of subclinical medical conditions and, therefore, the prevention of cardiovascular events.
1. Introduction
Obesity has been a health problem of growing signiﬁcance all
over the world; its prevalence is increasing in both developed
and developing countries [1]. According to WHO data, 39%
of the global population above 18 years of age are overweight
and of these, 13% are obese. Numerous studies have demon-
strated a relationship between obesity and cardiovascular dis-
eases (stable coronary disease, acute myocardial infarction,
heart failure, cardiac arrhythmias, and sudden cardiac
death). The association between obesity and hypertension,
diabetes mellitus, dyslipidaemias, and sleep apnoea syn-
drome has also been shown to increase the incidence of
cardiovascular disorders [2].
Bodymass index (BMI) is used for measuring the extent of
obesity; however, it gives no information on fat distribution,
which is of high signiﬁcance in cardiovascular risk [3].
Therefore, novel clinical measurements (e.g., abdominal
circumference and the calculation of waist/hip ratio) have
been introduced with the aim of characterizing central or
abdominal obesity. Abdominal circumference above 102 cm
in the case of men and above 88 cm in the case of women qual-
iﬁes as central obesity and involves increased cardiovascular
risk [4]. A waist/hip ratio above 0.9 in the case of men and
above 0.85 in the case of women indicates central obesity [5].
2. The Relationship between Obesity
and Atherosclerosis
In the past three decades, many details of the pathophysio-
logical processes of obesity and atherosclerosis have been
revealed. Previously, both diseases had been regarded as lipid
storage disorders with triglyceride accumulation in the fat
tissue and cholesterol esters in atherosclerotic plaques. Now-
adays, both obesity and atherosclerosis are considered
chronic inﬂammatory conditions, in which the activation of
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both nonspeciﬁc and adaptive immune processes is assigned
a signiﬁcant role [6, 7].
The pathogenesis of obesity and atherosclerosis has
several common factors. In both cases, lipids, oxidized LDL
particles, and free fatty acids activate the inﬂammatory pro-
cess and trigger the disease. Inﬂammation is responsible for
all the steps towards atherosclerosis, from early endothelial
dysfunction to the atherosclerotic plaques causing complica-
tions, and is related to obesity, insulin resistance, and type 2
diabetes. The fatty tissue releases adipocytokines, which
induce insulin resistance, endothelial dysfunction, hyperco-
agulability, and systemic inﬂammation, thereby facilitating
the atherosclerotic process. In visceral obesity, inﬂammatory
adipocytokines (e.g., TNF-α, IL-6, MCP-1, leptin, and
resistin) rise to higher levels. Moreover, the increased level
of C-reactive protein is associated with an increased risk of
myocardial infarction, peripheral vascular disease, and diabe-
tes mellitus [8–10]. Interestingly, a clinical study performed
on obese women conﬁrmed that body weight reduction
achieved through lifestyle changes reduces the level of inﬂam-
matory biomarkers and insulin resistance. In the course of the
process, adiponectin, an anti-inﬂammatory and insulin-
sensitizing adipocytokine, is released [11]. It is important to
understand the relationship between the inﬂammatory pro-
cess and atherosclerosis and the accelerating role of obesity.
3. Obesity and Coronary Artery Disease
Obesity is closely related to coronary atherosclerosis. A study
performed on young patients showed that atherosclerosis
begins several decades before manifested coronary artery dis-
ease. Atherosclerotic vascular lesions of patients with higher
BMI values are more frequent and advanced compared to
subjects with normal body weight [12]. According to
longitudinal studies, at least two decades of obesity is likely
to be an independent risk factor of coronary artery disease
[13, 14]. A 10 kg rise in body weight increases the risk of cor-
onary artery disease by 12% and at the same time, systolic
blood pressure rises by 3mmHg and diastolic by 2.3mmHg
as a consequence [15] (Figure 1). Furthermore, in the case
of non-ST segment elevation myocardial infarction
(NSTEMI) aﬀecting young people, excess weight can be con-
sidered the most important risk factor, ahead of smoking.
The higher the BMI, the sooner NSTEMI develops [16].
The same relationship can also be observed in the case of
ST elevation myocardial infarction (STEMI) [17]. Based on
the data available, obesity is an independent risk factor of
STEMI developing at a young age [18] but at the same time
excess weight can also be related to other vascular events.
An increase in BMI by one unit causes a 4% rise in the risk
of ischemic and a 6% rise in haemorrhagic strokes [19].
4. Obesity and Heart Failure
The frequency of heart failure is increasing; it is one of the
major causes of death globally with a prevalence of approxi-
mately 3% in developed countries [20]. A close correlation
can be observed between heart failure and obesity. According
to data from the FraminghamHeart Study, the rise of BMI by
1 kg/m2 increases the risk of heart failure by 5% in the case of
men and 7% in the case of women [21]. Studies on heart fail-
ure show that 32%–49% of patients suﬀering from heart fail-
ure are obese and 31%–40% are overweight. In the case of
obese and overweight patients, heart failure develops 10 years
earlier than in the case of subjects with a normal BMI. The
duration of morbid obesity is closely correlated to the devel-
opment of heart failure: after 20 years of obesity, the preva-
lence of heart failure grows by 70% and after 30 years, the
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Figure 1: The pathomechanism of coronary artery disease in obesity.
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prevalence rises by 90% [22]. The signiﬁcance of obesity is
indicated by the fact that the Framingham Heart Study
emphasized the pathogenic role of obesity for the develop-
ment of heart failure in 11% of males and 14% of females
[21]. The structural and functional changes of the heart
observed in obesity alone contribute to a deterioration in
myocardial function, which is often referred to as “obesity
cardiomyopathy” [23].
Obesity leads to heart failure through several direct and
indirect mechanisms. Excess weight leads to haemodynamic
changes. A rise in both cardiac output and blood pressure
has been observed; an increase in BMI of 5 kg/m2 involved
a 5mmHg rise in systolic blood pressure [24]. On one hand,
it is related to the activation of the renin-angiotensin-
aldosterone system and on the other hand, to the increased
activity of the sympathetic nervous system [25, 26]. Obesity
increases both the aldosterone level and the mineralocorti-
coid receptor expression, which promote interstitial cardiac
ﬁbrosis, platelet aggregation, and endothelial dysfunction.
The above mechanisms explain the results of EMPHASIS-
HF trial: eplerenone therapy was more beneﬁcial for treat-
ment of heart failure with reduced ejection fraction in
patients with abdominal obesity [27, 28]. Increased blood
volume facilitates venous backﬂow, which enhances ventric-
ular preload causing increased ventricular wall tension and
ultimately leading to ventricular dilatation. Abdominal obe-
sity is associated with subclinical left ventricular dysfunction
[29]. Hypertension increases left ventricular afterload, which
raises the danger of structural and electrical myocardial
remodelling. This process ultimately leads to left ventricular
hypertrophy and to diastolic and later to systolic ventricular
dysfunction [30].
Inﬂammatory cytokines (TNF-α, IL-1, IL-6, IL-8, etc.),
whose production is increased in obesity, also play an impor-
tant role in the development of heart failure [31–33]. The
inﬂammatory mediators and acute-phase proteins in circula-
tion cause myocardial ﬁbrosis, which increases myocardial
stiﬀness and may thereby lead to diastolic and later to systolic
heart failure [34]. Through their eﬀect on metabolism, tissue
structure, and the extracellular matrix, leptin and adiponec-
tin contribute directly to the myocardial transformation.
Triglyceride accumulation in the cardiac muscle can regu-
larly be observed in obese patients and facilitates the genera-
tion of toxic metabolites (e.g., ceramide and diacylglycerol),
thus enhancing the apoptosis of cardiomyocytes [35–37].
The integrity of skeletal muscle mass is crucial for retaining
the physical activity. Diet-induced obesity has been shown
to promote muscle atrophy and catabolism. This process
plays an important role in the progression of CVD in obese
patients [38].
Moreover, obesity has been shown to increase the
chances of heart failure not only by itself but also through
the associated medical comorbidities. The frequently
appearing insulin resistance reduces the contractility of
the myocardium [39], while it enhances the activity of the
renin-angiotensin-aldosterone system, which can result in
hypertrophy and apoptosis of cardiac myocytes and to myo-
cardial ﬁbrosis [40]. Alterations in lipid metabolism enhance
atherosclerosis and thereby the risk of ischemic cardiomyop-
athy. Unsurprisingly, obesity is therefore an independent risk
factor of coronary artery disease [41]. Myocardial lipid accu-
mulation and enhanced ﬁbrosis can also play a pathogenic
role in the genesis of various cardiac arrhythmias, which
may contribute to the development of heart failure [42, 43]
(Figure 2).
5. Obesity and Cardiac Arrhythmias
Numerous studies have demonstrated the connection
between obesity and the increased risk of cardiac arrhythmias
and sudden cardiac death [44, 45]. Hippocrates concluded in
the 4th century already that “sudden death is more common
in those who are naturally fat than in the lean.”
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Figure 2: The pathomechanism of heart failure in obesity.
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5.1. Obesity and Atrial Fibrillation. Among the cardiac
arrhythmias, atrial ﬁbrillation has the highest clinical signiﬁ-
cance. Its incidence and prevalence is increasing worldwide,
aﬀecting 1–2% of the adult population. Atrial ﬁbrillation is
responsible for about one third of the hospitalizations due
to arrhythmias; it signiﬁcantly increases morbidity, mortal-
ity, and health care expenditure. Over 6 million Europeans
suﬀer from this type of arrhythmia, and this number is esti-
mated to double in the next ﬁfty years [46]. The occurrence
of atrial ﬁbrillation shows a correlation with age; its fre-
quency among people aged 40–50 is under 0.5%, while it rises
to 5–10% by the age of 80 years. Various studies have proven
the relationship between obesity and atrial ﬁbrillation. Obese
patients have a 1.52 times higher risk for the development of
atrial ﬁbrillation compared to the normal weight population
[45, 47, 48]. A 1-unit rise in BMI increases the frequency of
newly developed atrial ﬁbrillation by 4%. At the same time,
in patients with atrial ﬁbrillation, there is an increased risk
for sudden cardiac death, stroke, thromboembolic complica-
tions, and heart failure. Moreover, atrial ﬁbrillation lengthens
hospitalization and worsens quality of life and physical
capacity [46].
5.2. Structural and Electrical Remodelling Caused by Obesity.
Obesity causes numerous anatomical and functional changes
which play an important role in arrhythmogenesis. Left atrial
dilation and dysfunction are known consequences of obesity.
A 5mm increase in left atrial cross diameter has been shown
to raise the chances of paroxysmal atrial ﬁbrillation 1.39
times [49]. Furthermore, recent studies have conﬁrmed the
correlation between increased epicardial fat tissue and atrial
ﬁbrillation. Through its paracrine eﬀect, epicardial fat con-
tributes to the development of atrial interstitial ﬁbrosis. The
increased epicardial fat, the inﬁltration of myocardium with
adipocytes, and ﬁbrosis together result in a heterogeneous
atrial pulse conduction, e.g., anisotropy, which contributes
to endo- and epicardial electrical dissociation [50–52]. All
these processes facilitate the development of atrial reentry,
which serves as the electrophysiological background of
atrial ﬁbrillation. Tests on both animals and humans have
proven that the expansion of fatty tissue is strongly associated
with insuﬃcient capillarisation, thus myocardial hypoxia.
Increased adipocyte necrosis triggers macrophage, neutro-
phil, and lymphocyte inﬁltration as well as the accumulation
of proinﬂammatory cytokines [53] (Figure 3). It has also been
proven that atrial ﬁbrillation in obese patients shortens the
refractory period of the atrial and pulmonary veinmyocardial
cells [54]. Enhanced adiposity triggers alterations in the ECG,
too: higher amplitude P waves with lengthened duration,
longer PR time, and P wave terminal force [55]. Animal
research ﬁndings reveal that diet-induced obesity may be
associated with prolonged atrial conduction time and hetero-
geneous pulse conduction. The same electrical changes were
observed in the case of atrial interstitial ﬁbrosis, increased
inﬂammatory activity, and myocardial lipid accumulation.
Remarkably, similar changes were registered in cases of con-
gestive heart failure, hypertension, andmyocardial infarction.
However, the pathogenic role of complex signalisation path-
ways (TGF, cTGF, and endothelial system) in atrial ﬁbrosis
is not yet precisely elucidated [56].
5.3. The Role of Obesity and Low-Grade Inﬂammation in
Arrhythmogenesis. The reason underlying atrial ﬁbrillation
is assumed to be the low-grade inﬂammation, which is
mainly observed in relation to obesity. In obese patients, an
increased number of leukocytes and a heightened presence
of various inﬂammatory cytokines (C-reactive protein, inter-
leukin-6, and tumor necrosis factor-α) were detected. TNF-α
may increase the local arrhythmic vulnerability of the pulmo-
nary vein, thereby causing atrial ﬁbrillation [57, 58]. TGF-β
plays an important role in the development of myocardial
ﬁbrosis [59] (Figure 3). The leptin released from adipocytes
lengthens the duration of the action potential and thereby
may have an arrhythmogenic eﬀect. The roles of low-grade
inﬂammation and oxidative stress in arrhythmogenesis have
not been clearly identiﬁed yet. All the above observations
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Figure 3: The pathomechanism of atrial ﬁbrillation in obesity.
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are associative, so the association through inﬂammation
remains a hypothesis only. Modiﬁcations of the ion chan-
nel function and calcium homeostasis disorder are also
assumed to be underlying phenomena [60].
5.4. Further Arrhythmogenic Factors Associated with Obesity.
In the case of atrial ﬁbrillation, the level of atrial natriuretic
peptide signiﬁcantly rises and shows correlationwith expected
mortality [61]. Additionally, in patients suﬀering from atrial
ﬁbrillation, the activation of the renin-angiotensin system
may be associated with atrial ﬁbrosis and electrical remodel-
ling [62]. Furthermore, obesity may cause autonomous ner-
vous system dysfunction. In the case of overweight patients,
excessive sympathetic activity and decreased vagal tone and
consequently increased urine norepinephrine secretion and
cardiac rhythm disturbances were detected [63].
6. Obesity and Sudden Cardiac Death
Various studies indicate a relationship between sudden
cardiac death and obesity [64]. Obesity is considered an inde-
pendent risk factor in the development of ventricular tachy-
arrhythmias. The structural remodelling in the ventricular
myocardium of obese patients results in left ventricular
hypertrophy and consequential systolic and diastolic ventric-
ular dysfunctions. Myocardial hypertrophy, ﬁbrosis, focal
myocardial disarray, and increased volume of epicardial fat
are also parts of the pathological process [65].
Obesity may also be associated with prolonged and
inhomogeneous ventricular repolarization, which can man-
ifest in the prolongation of the QT interval and QT interval
corrected to the heart rate (QTc) measured on the 12-lead
surface electrocardiogram. These ECG parameters are
known as independent markers of cardiovascular mortality,
and their pathological prolongation may draw attention to
an increased risk of ventricular arrhythmias [66]. In the
development of the pathologically prolonged and inhomo-
geneous repolarization observed in obesity and the electrical
instability involved as a consequence, the main roles are
assigned to obesity cardiomyopathy, the altered function
of voltage-dependent potassium channels, and autonomic
dysregulation [67, 68].
7. The Obesity Paradox
Even though obesity involves enhanced risk for the develop-
ment of cardiovascular abnormalities, in the case of an
already developed disease, excess weight and obesity are
associated with a favorable prognosis. The phenomenon
known as obesity paradox has been observed in the case
of several cardiovascular diseases including acute and
chronic heart failures [69, 70], coronary artery disease [71],
acute myocardial infarction [72], hypertension, and atrial
ﬁbrillation [73, 74].
7.1. The Obesity Paradox and Heart Failure. In the case of
patients suﬀering from heart failure, the ﬁndings of numer-
ous meta-analyses have proven the phenomenon of the
obesity paradox.
According to a meta-analysis processing observational
studies and summarizing the data of 28,209 patients alto-
gether, during a follow-up time of 2.7 years on the average,
in the case of overweight persons with heart failure, overall
mortality was 16% lower and cardiovascular mortality was
19% lower compared to the control group. The above data
are even more favorable in the case of obese patients with
heart failure: overall mortality rate was 33% lower and car-
diovascular mortality was 40% lower compared to normal
weight patients [70].
According to a more recent meta-analysis processing the
data of 22,807 patients, during an average follow-up time of
2.85 years, the relative risk of overall death in the case of
overweight patients with heart failure was 0.78 (conﬁdence
interval 0.68–0.89), the relative risk of cardiovascular death
was 0.79 (conﬁdence interval 0.7–0.9), and that of hospitali-
zation was 0.92 (conﬁdence interval 0.86–0.97) compared
to normal weight patients with heart failure. At the same
time, no favorable changes were observed in the case of obese
patients either in cardiovascular mortality or in hospitaliza-
tion; only the risk of overall mortality was lower compared
to normal weight patients [75].
The analysis of Heart Failure Registry of the Heart Failure
Association of the European Society of Cardiology showed
inverse relationship between all-cause and cardiovascular
mortality and body surface area (BSA) levels. Hospitaliza-
tions due to heart failure were not associated with BSA [76].
7.2. The Obesity Paradox and Coronary Revascularisation.
The correlation between BMI and the outcome of clinical
revascularisation was ﬁrst reported in 1996, in the case of
patients who had been administered balloon coronary angio-
plasty. According to the hospital ﬁndings, the mortality rate
was higher in the case of normal weight and obese patients
than in that of overweight patients [77].
Data of the multicentre BARI register processing the data
of 3634 patients administered coronary revascularisation
(primary coronary intervention (PCI) with catheter or surgi-
cal coronary revascularisation (CABG)) reveal that in the
acute hospitalization period, there was an inverse relation-
ship between complications and BMI only in the case of
PCI-treated patients. Remarkably, in the case of the CABG
group, there was an inverse relationship between mortality
and BMI only 5 years after the operation [78]. It must be
emphasized that clinical events following surgery, like arte-
rial hypotension, pulmonary oedema, the deterioration of
kidney function, bleeding, and mortality, were more fre-
quent in the case of thin than in that of overweight or
obese patients.
According to data of the Scottish Coronary Revasculari-
sation Register, in the case of patients who had not suﬀered
from coronary artery disease before and who underwent
elective PCI intervention, lower mortality rate was observable
in the next 5 years if their BMI value was between 27 and
30 kg/m2 [79].
According to data of the APPROACH register, mortality
following PCI and CABG was more favorable in the case of
overweight or obese persons compared to those with normal
body weight [80].
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On the contrary, other studies on coronary stent implan-
tation did not support the phenomenon of the “obesity
paradox.”
Interestingly, in the course of using traditional bare metal
stents (BMS), an inverse relationship could be observed
between BMI and clinical outcome. In the case of BMS
implantation, obesity was an independent predictor of in-
stent restenosis. However, a relationship between obesity
and adverse events was, surprisingly, not conﬁrmed after
drug-eluting stent (DES) implantation [81].
At the same time, it is still disputed if obese coronary
artery disease patients would beneﬁt from DES implantation.
According to data from the German DES.DE register, the
rate of hospital complications did not diﬀer in the cases of
normal weight, overweight, or obese patients. At the time of
the one-year follow-up, there was similarly no diﬀerence in
mortality, myocardial infarction, target vessel revascularisa-
tion, or bleeding complications [82].
7.3. Explanation for the Obesity Paradox. It is well known
that excess weight and obesity, as phenomena of the meta-
bolic syndrome, lead to enhanced cardiovascular risk, endo-
thelial dysfunction, inﬂammation, and atherosclerosis. The
most important question is what can the explanation be for
the better prognosis established in the case of overweight
and obese cardiovascular patients compared to normal
weight patients.
The analyses show that in the case of 2% of thin patients,
comorbid conditions, mostly malignant diseases, heart fail-
ure, malnutrition, or multiple organ dysfunction, can be
observed. Moreover, these patients were much older than
their normal weight or obese counterparts [78, 83]. Obvi-
ously, in the case of older age patients in a generally weak
condition, clinical outcomes after coronary events proved
to be worse irrespective of the success of the reperfusion
[84]. Advanced age and comorbid factors often result in loss
of body weight [85]. In obesity, the increased level of serum
lipoproteins may neutralize bacterial toxins and circulating
cytokines [86]. The low level of adiponectin and the reduced
catecholamine response, too, may increase the chances of
survival [87]. Furthermore, in the case of obese patients, car-
diovascular diseases are usually diagnosed and treated earlier
than in the case of thin patients [88]. In the case of over-
weight and obese patients, the dose of medication required
in treating the cardiovascular disease is easier to titrate con-
sidering the associated hypertension and obese patients are
also more compliant with regimen than their normal weight
counterparts. A possible explanation of obesity paradox is
that in critical ill patients, fat which mobilized from excess
adipose tissue provides energy and prevents lean tissue wast-
ing more eﬃciently than exogenous nutrients [89]. In heart
failure, a metabolic cardiac remodeling occurs, the fatty acid
oxidation is impaired, and the glucose uptake and glycolysis
are increased. The metabolic imbalance between higher
energetic demand and substrate availability and lower oxida-
tive capacity and cofactor availability (carnitine and CoA)
leads to the accumulation of intermediates, which impair
cardiac function, and substrates are diverged towards lipo-
toxic signaling pathways [90]. Alterations in mitochondrial
dynamics, respiratory capacity, and ATP synthesis play an
important role in the chronic cardiac energy deﬁcit observed
in heart failure [91]. Improved fatty acid utilization via die-
tary modiﬁcation signiﬁcantly ameliorates mitochondrial
fragmentation and cardiac dysfunction [92].
According to more recent theories explaining the “obe-
sity paradox,” obese patients have “larger blood vessels”
and in the course of PCI, worse results are obtained in the
case of patients with narrowed blood vessels [93, 94].
Antithrombotic medication is usually administered in
standard doses rather than adjusted to body weight, so the
dose may be too high for normal weight and thin patients,
which may result in bleeding complications and this, in turn,
may also contribute to higher mortality [95].
If the outcomes of cardiopulmonary stress tests are also
considered, the favorable eﬀect of higher BMI was shown to
disappear [96]. According to other views, the greater muscle
strength associated with a higher BMI has a favorable eﬀect
on so-called “cardiorespiratory ﬁtness” [97, 98]. Peak oxygen
consumption (VO2) is a positive predictor of longer survival
among patients with heart failure. In multivariate analysis
using VO2, the protective role of BMI for survival disappears
[99]. The survival paradox of BMI disappears also in diabetic
patients with heart failure [100]. These results support the
superior prognostic power of peak oxygen consumption
and diabetes compared to obesity, which attenuates the
“obesity paradox” phenomenon [101].
According to the endotoxin-lipoprotein hypothesis,
obese patients have higher cholesterol and lipoprotein levels,
which reduce the concentration of inﬂammatory agents and
may thus have anti-inﬂammatory and probably also arrhyth-
mia protective eﬀect. The observation that the myocardial
accumulation of fat enhances the density of TNF-α I and II
receptors, thereby facilitating the development of an antiar-
rhythmogenic environment, may at the same time probably
serve as a kind of explanation for the development of the
obesity paradox [57, 58].
8. Cardiac Consequences of the Haemodynamic
Changes Triggered by Obesity
The volume stress associated with obesity causes both struc-
tural and functional changes in the heart. The most frequent
structural changes are left ventricular hypertrophy (LVH)
and left ventricular dilation, and as a consequence, diastolic,
then systolic dysfunction, epicardial fat accumulation, and
left atrial enlargement occur. The circulating blood volume
rises; the increased cardiac output is provided mainly by
the increased stroke volume and, to a lesser extent, by the
increased cardiac frequency as an eﬀect of the enhanced
sympathetic tone. The above mechanisms often cause hyper-
tension [23] (Figure 2).
9. Cardiology Diagnostics in Obesity
Considering the enhanced cardiovascular risk and inclina-
tion to arrhythmia observed in obesity, cardiology
diagnostics are important even in the case of symptom-
free obese patients. The routine 12-lead surface ECG and
6 Journal of Diabetes Research
echocardiography are available at almost any cardiology
outpatient unit nowadays.
9.1. Echocardiography. According to a meta-analysis pub-
lished in 2014, the frequency of left ventricular hypertrophy
(LVH) in obese patients is 56%; the risk of the develop-
ment of LVH in the case of obese patients is 4.19 times
higher than in the case of people with normal weight.
Excentric hypertrophy is more frequent than the concentric
type (66% vs. 34%, p < 0 001) [102]. LVH is usually calcu-
lated by the left ventricular mass index (LVMI), whereby it
is indexed to height2.7. This shows a good correlation with
cardiovascular mortality. Less frequently, indexation to
body surface area is used [103].
In obesity, the prevalence of diastolic dysfunction is
above 50% and shows close correlation with abdominal
circumference. Among cardiovascular risk factors, age,
sex, and hypertension increase the likelihood of diastolic
dysfunction, which is demonstrated by what is referred
to as the E/A ratio: the ratio of the mitral ﬂow velocities
measured in the early diastole (E) and late diastole (A).
The value of the ratio is less than 1 in the case of diastolic
dysfunction, primarily due to a rise in the peak velocity of
A. The diagnosis also requires establishing the so-called
deceleration time, i.e., the time taken from the peak to
the end of the A wave, while the velocities of the mitral
annular longitudinal movement obtained by the tissue
Doppler imaging technique constitute further complemen-
tary and speciﬁcation data (Figure 4). Left atrial volume
enlargement is also often associated with diastolic dysfunc-
tion and can thus be considered as a marker of the latter
[104]. At the same time, conventional echocardiography is
sometimes unsuitable for the early diagnosis of systolic or
diastolic dysfunction as the measurable parameters may
still be in the normal range.
In the past decade, new echocardiographic techniques
have become available that make a yet earlier diagnosis of
systolic and diastolic dysfunctions possible [105]. Color
Doppler imaging detects the movement and deformity of
the myocardium and is thereby able to show changes in
contractility [106]. The so-called “integrated backscatter”
technique is able to sense changes in the reﬂectivity and
weakening of the myocardium. These are primarily deter-
mined by the myocardial collagen content and are also
inﬂuenced by the size and microstructure of cardiac mus-
cle cells. The technique primarily provides information on
myocardial stiﬀness, contractility, and the extent of ﬁbro-
sis, in a noninvasive way [107, 108]. Pulsatile wave tissue
Doppler imaging (PW-TDI) measures the cardiac muscle
movement velocity. These Doppler parameters are more
precise and easier to reproduce than those obtained by
means of 2D, M-mode echocardiography [109]. 3D imag-
ing has lately been introduced in cardiology as well, which
makes the determination of the ejection fraction (EF) and
the volume of the left atrium and the left ventricle more
precise [110]. A comparison with MRI imaging proved
the advantages of 3D echocardiography.
9.2. Electrocardiography. In case of obesity, the QT interval
corrected to the heart rate (QTc) is prolonged and QT disper-
sion (QTd) also increases [111, 112]. These electrocardio-
graphic diﬀerences show a correlation with an enhanced
disposition to ventricular arrhythmia. In the past two
decades, new markers of ventricular repolarization have been
identiﬁed, which characterize cardiac muscle vulnerability in
coronary artery disease, hypertrophic cardiomyopathy, and
long QT syndrome very well: T peak-end (Tpe) interval, T
peak-end dispersion, and Tpe/QT ratio (arrhythmogenic
index) [113–115]. Studies performed on obese patients
showed, however, that statistically signiﬁcant prolongation
compared to the control values was observed only in the case
of QT interval and QTc; there were no similar diﬀerences
observed in the case of the other electrocardiographic param-
eters [116].
Using the above testing procedures, the slight struc-
tural, electrical, and functional changes of the heart can
be detected. Consequently, symptom-free patients with
enhanced risk for ventricular arrhythmias can be identiﬁed
at an early stage.
10. Summary
Excess weight and obesity are associated with an increased
risk of cardiovascular diseases. This is a consequence on the
one hand of obesity itself and on the other hand of associated
medical conditions (hypertension, diabetes, insulin resis-
tance, and sleep apnoea syndrome). In case of already estab-
lished cardiovascular diseases, the mortality of overweight
and obese patients is often lower than that of people with a
normal body weight, which is known as “obesity paradox.”
The exact mechanism of the latter is not clear yet. Consider-
ing the increased cardiovascular risk, the regular cardiology
screening, and control of still symptom-free obese patients
is important for the early diagnosis and treatment of
subclinical medical conditions.
Figure 4: Diagnosing diastolic dysfunction with echocardiography.
Transmitral ﬂow velocities measured with pulsatile wave Doppler
technique. The ratio (E/A) of the early diastolic peak velocity (E)
and the late diastolic velocity (A) is lower than 1. Deceleration
time (DT) is the interval from the peak of the wave E to its end
(marked with a yellow line). In this case, its prolongation was
measured (310 sec). The above alterations prove the left
ventricular diastolic dysfunction (relaxation disorder).
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